All Trials

A Phase I Open-label, Multi-dose, Dose Escalation and Dose Expansion Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: This trial enrolls adults with advanced NSCLC harboring EGFR mutations—including exon 20 insertions, classical (Ex19del, L858R), uncommon, or T790M drug-resistant mutations—to receive oral PLB1004, a novel irreversible EGFR tyrosine kinase inhibitor designed for broad activity across EGFR mutations with selectivity over wild-type EGFR.

ClinicalTrials.gov ID: NCT06046495

A Phase I/II Study Evaluating the Safety and Efficacy of Ivermectin in Combination With Balstilimab in Patients With Metastatic Triple Negative Breast Cancer With Expansion Cohort in PD-L1 Negative TNBC

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Eligible patients are adults with metastatic triple negative breast cancer who have progressed on one to two prior systemic therapies and have not received prior checkpoint inhibitors in the metastatic setting; the trial evaluates oral ivermectin (an antiparasitic agent with potential anticancer effects) in combination with either balstilimab (an investigational anti-PD-1 antibody) or pembrolizumab, with a focus on PD-L1 negative disease in the phase 2 cohort.

ClinicalTrials.gov ID: NCT05318469

Phase I/II Study of Stereotactic Radiation and Sacituzumab Govitecan With Zimberelimab in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases (TARGET-TNBC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Eligible patients are adults with metastatic triple-negative breast cancer and measurable brain metastases who can undergo stereotactic radiosurgery; treatment consists of SRS followed by sacituzumab govitecan (an anti-Trop-2 antibody-drug conjugate) and zimberelimab (a PD-1 inhibitor immunotherapy). Prior taxane/anthracycline or SRS/FSRT therapy (if new lesions) is allowed; key exclusions are leptomeningeal disease, significant comorbidities, active autoimmune disease requiring immunosuppression, and prior topoisomerase I inhibitor use for brain metastases.

ClinicalTrials.gov ID: NCT06238921

Innovative Combination Immunotherapy for Metastatic Triple Negative Breast Cancer (TNBC): A Multicenter, Multi-Arm Translational Breast Cancer Research Consortium Study

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial enrolls adults with metastatic or unresectable, recurrent triple negative breast cancer (TNBC) who have had up to two prior lines of chemotherapy and limited prior immunotherapy, randomizing them to receive avelumab (PD-L1 inhibitor) combined with either liposomal doxorubicin, liposomal doxorubicin plus binimetinib (MEK inhibitor), or sacituzumab govitecan (TROP2-directed antibody-drug conjugate). Patients must have measurable disease, ECOG 0-1, and be biopsy-amenable.

ClinicalTrials.gov ID: NCT03971409

A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study of RBS2418 Plus Best Supportive Care (BSC) in Subjects with Advanced, Metastatic, and Progressive Colorectal Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Low burden on patient

The trial has a low burden on patients. An example would be a trial testing an oral drug, with scans every 12 weeks which would be similar to standard of care.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

TrialFetch AI summary: This trial enrolls adults with advanced, metastatic, and progressive colorectal cancer who have failed or are ineligible for all standard therapies, comparing best supportive care with or without RBS2418, an oral selective ENPP1 inhibitor that stimulates anti-tumor immunity via the cGAS-STING pathway. Patients must have measurable disease and ECOG 0–2, with stratification by ENPP1 and cGAS status.

ClinicalTrials.gov ID: NCT06824064

A Phase 1/2 Clinical Trial of Quaratusugene Ozeplasmid and Atezolizumab Maintenance Therapy in Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Maintenance trial for adults with ES-SCLC who have CR/PR/SD after 3–4 cycles of carboplatin/etoposide/atezolizumab (ECOG 0–1; treated, asymptomatic brain mets allowed), testing atezolizumab ± hyaluronidase every 21 days combined with quaratusugene ozeplasmid (Reqorsa), a non-viral lipid nanoparticle gene therapy delivering TUSC2 tumor suppressor to restore tumor suppression, disrupt oncogenic signaling, induce apoptosis, and enhance anti-tumor immunity. RP2D of quaratusugene ozeplasmid is 0.12 mg/kg IV every 21 days.

ClinicalTrials.gov ID: NCT05703971

Phase I Study of Valemetostat and Atezolizumab as Maintenance Therapy for Patients With Extensive-Stage Small Cell Lung Cancer

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with newly diagnosed extensive-stage SCLC who have SD/PR/CR after 4 cycles of platinum doublet plus atezolizumab start maintenance atezolizumab (standard dosing) combined with oral valemetostat, an investigational dual EZH1/EZH2 inhibitor targeting H3K27me3 to suppress tumor proliferation. Key allowances include treated, controlled brain mets; key exclusions include recent consolidative chest RT, significant cardiac comorbidities/QTc prolongation, active infections, strong CYP3A modulators, and prior EZH inhibitor use.

ClinicalTrials.gov ID: NCT06807632

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Enrolling adults with advanced solid tumors requiring an injectable lesion: first-line PD-1–eligible HNSCC (PD-L1 CPS ≥1%, no prior PD-(L)1), cutaneous melanoma with primary resistance or progression on prior PD-(L)1 (BRAF+ should have received/declined targeted therapy), and a closed-to-enrollment non–MSI-H CRC cohort; ECOG 0–1 required. Treatment is intratumoral VV1 (VSV engineered to express IFN-β and NIS; oncolytic/immune-stimulatory) combined with IV cemiplimab every 3 weeks until progression/toxicity.

ClinicalTrials.gov ID: NCT04291105

A Phase II, Multicentre, Open-label, Master Protocol to Evaluate the Efficacy and Safety of Datopotamab Deruxtecan (Dato-DXd) as Monotherapy and in Combination With Anticancer Agents in Patients With Advanced/Metastatic Solid Tumours

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: Adults with advanced/metastatic solid tumors (endometrial, gastric, mCRPC, ovarian, colorectal, urothelial, biliary) receive datopotamab deruxtecan (anti‑TROP2 antibody–drug conjugate delivering a topoisomerase I inhibitor) as monotherapy or combined with agents such as capecitabine/5‑FU, bevacizumab ± platinum, prednisone (mCRPC), platinum in urothelial cancer, or bispecific PD‑1/CTLA‑4 (volrustomig) or PD‑1/TIGIT (rilvegostomig) immunotherapies. Key exclusions include active/untreated CNS disease, prior TROP2- or deruxtecan-based ADCs, significant ILD/pneumonitis history, and uncontrolled infections/comorbidities.

ClinicalTrials.gov ID: NCT05489211

A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults and adolescents (≥15) with recurrent IDH1/2-mutant diffuse glioma (WHO grade 2–4) after prior radiation and/or chemotherapy receive intermittent oral zotiraciclib monotherapy. Zotiraciclib is an investigational multi-kinase, CDK9-focused inhibitor that suppresses RNA Pol II–dependent transcription (e.g., MCL-1/MYC pathways); a surgical PD cohort gets a single pre-resection dose with post-op resumption.

ClinicalTrials.gov ID: NCT05588141